What is Zacks Research’s Estimate for STERIS Q4 Earnings?

STERIS plc (NYSE:STE) – Stock analysts at Zacks Research lifted their Q4 2026 earnings per share (EPS) estimates for shares of STERIS in a research note issued to investors on Tuesday, October 21st. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $2.86 per share for the quarter, up from their prior estimate of $2.85. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q1 2027 earnings at $2.47 EPS and Q2 2028 earnings at $3.08 EPS.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The firm had revenue of $1.40 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the business earned $2.03 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year.

STE has been the subject of a number of other reports. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Morgan Stanley raised their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Finally, KeyCorp upped their price target on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Price Performance

Shares of STE opened at $241.87 on Thursday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. STERIS has a 1-year low of $200.98 and a 1-year high of $253.00. The stock has a market cap of $23.82 billion, a PE ratio of 37.04 and a beta of 1.01. The firm has a fifty day moving average price of $244.87 and a 200 day moving average price of $236.91.

Institutional Trading of STERIS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STE. Foresight Group Ltd Liability Partnership purchased a new position in shares of STERIS during the 1st quarter worth about $25,958,000. Ascent Group LLC purchased a new position in STERIS during the first quarter worth approximately $261,000. Allianz Asset Management GmbH boosted its holdings in shares of STERIS by 31.9% in the 1st quarter. Allianz Asset Management GmbH now owns 102,488 shares of the medical equipment provider’s stock valued at $23,229,000 after purchasing an additional 24,809 shares during the last quarter. NorthRock Partners LLC grew its stake in shares of STERIS by 21.8% during the 2nd quarter. NorthRock Partners LLC now owns 1,290 shares of the medical equipment provider’s stock valued at $310,000 after buying an additional 231 shares during the period. Finally, Truist Financial Corp increased its holdings in shares of STERIS by 116.2% during the 2nd quarter. Truist Financial Corp now owns 31,064 shares of the medical equipment provider’s stock worth $7,462,000 after buying an additional 16,694 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,495 shares of STERIS stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.56, for a total transaction of $844,252.20. Following the completion of the sale, the director directly owned 705 shares in the company, valued at $170,299.80. The trade was a 83.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel A. Carestio sold 159 shares of the business’s stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer owned 51,096 shares of the company’s stock, valued at $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,868 shares of company stock valued at $4,585,389. Corporate insiders own 1.07% of the company’s stock.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, September 4th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. This is an increase from STERIS’s previous quarterly dividend of $0.57. STERIS’s dividend payout ratio is 38.59%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.